Why the study?
Does NOAC therapy improve health-related quality of life compared to vitamin K antagonists in patients with atrial fibrillation undergoing electrical cardioversion?
Does NOAC therapy improve health-related quality of life compared to vitamin K antagonists in patients with atrial fibrillation undergoing electrical cardioversion?
While NOACs offer better initial health-related quality of life compared to VKAs in patients with atrial fibrillation, this advantage dissipates by 6 months as patients adapt to VKA therapy.
Similar 6-month HRQoL supports flexible VKA/NOAC choice post-cardioversion; leaves open confirmation in randomized trials.
New oral anticoagulants (NOAC) have demonstrated their efficacy as an alternative to vitamin K antagonists (VKA) in the prophylaxis of cardioembolic events in patients with atrial fibrillation (AF). However, evidence on the benefits of NOAC in health-related quality of life (HRQoL) is lacking.We evaluated changes in HRQoL related to oral anticoagulation therapy employing a specific questionnaire in a cohort of 416 patients with AF undergoing electrical cardioversion. In terms of HRQoL, we observed a progressive adaptation to treatment with VKA; satisfaction with NOAC remained constant. Older age, higher left ventricular ejection fraction and NOAC were associated with better HRQoL.
No takes yet. Share an insight, caveat, or question.
Alegret et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: